While speaking at the National Association of Accountable Care Organizations Spring 2016 Conference, Stephen Nuckolls, CEO of Coastal Carolina Quality Care, said that fair and transparent benchmarks are important in creating successful ACO programs.
While speaking at the National Association of Accountable Care Organizations Spring 2016 Conference, Stephen Nuckolls, CEO of Coastal Carolina Quality Care, said that fair and transparent benchmarks are important in creating successful ACO programs.
Transcript (slightly modified)
What is your view on the new ACO benchmarking rule?
This new benchmarking rule is very important. How we keep score in the Medicare ACO program is vital to our long-term business prospects. We must have fair and transparent benchmarks in order for the program to be successful, especially when it comes to groups taking downside risk. They not only have to be transparent but they also have to be very predictable in order for groups to take risk.
There are many different facets of the new benchmarking proposal that are very good. For example, with the original program, the benchmarks were adjusted based on all fee-for-service beneficiaries. Under the new rule, they have proposed that the fee-for-service comparison is just for attributable beneficiaries. And that may seem like a small distinction but I think it’s going to have a bigger impact on the benchmarks.
It’s my opinion that the way CMS has been keeping score in the past understates the savings that have actually been achieved by the organizations. As evidence of that, the data that CMS provided us with the most recent proposed rule, the number of attributable beneficiaries by county along with their risk scores. And so when we took that data and compared the ACO performance against the country benchmarks excluding the ACO’s, there was a 3% difference between the 2 figures. Meaning that ACOs performed 3% better. I don’t believe that they were lower price coming into the program. In fact, the ACO program incentivizes high cost providers to go into the program because of the way the benchmarks were structured. So the actual savings may be somewhere well north of 3% when the CBO scores and other things have looked at it, it showed 1% or less.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More